The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03186326
Recruitment Status : Active, not recruiting
First Posted : June 14, 2017
Last Update Posted : August 19, 2022
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive

Brief Summary:

Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC). However, the MSI CRC representing approximately 15% of the CRCs exhibits a high mutational load which generates many potentially immunogenic neoantigens. In addition, strong expression of PD-L1 was found in the MSI CRCs relative to the CRC (MSS) stages. Localized MSI CRCs have a better prognosis than MSS CRCs, probably due to immunogenic neoantigens associated with a CD8 + T-specific immune response. On the oher hand, in metastatic CRC (mCRC) things are different because i) the MSI frequency is only 4 to 7% and ii) the good prognosis conferred by the MSI status is controversial.

Preliminary results suggest that patients with MSI mCRC are highly sensitive to ICI even chemoresistant tumors receiving several lines of chemotherapy. Recently, another anti-PD1 alone or in combination with an anti-CTLA4 (antigen associated with cytotoxic T-lymphocyte 4) was tested in the MSI CRCs and a selection of interesting results in heavily pretreated patients with a disease control rate of 56% for monotherapy and 81% for combinated therapy.

Anti-PD1s now have marketing authorization for patients with melanoma and metastatic pulmonary carcinoma , Which are known to have a high level of mutations . ICIs appear to be as promising in MSI CRCs as in other tumors and therefore face the same major challenges.

Avalumab is an anti-PD-L1 antibody recently tested in several different types of tumors with promising results and is currently being studied in phase III in gastric cancer. There is no data on the effectiveness of this ICI in the MSI mCRCs. In addition, only anti-PD1 was used in the MSI-mCRC and not the anti-PD-L1, and only in chemoresistance (3rd line or more). The main objective of the SAMCO study is to test the efficacy and tolerance of avelumab in the 2nd line of treatment in patients with a MSI mCRC progression after standard 1st line chemotherapy +/- targeted therapy.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer MSI Drug: FOLFOX regimen Drug: FOLFIRI Protocol Drug: Avelumab Drug: Panitumumab Drug: Cetuximab Drug: Bevacizumab Drug: Aflibercept Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Actual Study Start Date : April 24, 2018
Actual Primary Completion Date : May 31, 2022
Estimated Study Completion Date : May 31, 2023

Arm Intervention/treatment
Active Comparator: Arm A Chemotherapy (standard treatment)
FOLFOX or FOLFIRI +/- targeted therapy
Drug: FOLFOX regimen

A course of treatment every 14 days

Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours

Drug: FOLFIRI Protocol

A course of treatment every 14 days

Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours

Drug: Panitumumab
Administered at 6 mg/Kg

Drug: Cetuximab
Administered at 500 mg/m²

Drug: Bevacizumab
Administered at 5 mg/Kg

Drug: Aflibercept
Administered at 4 mg/Kg

Experimental: Arm B - Immunotherapy (experimental arm)
Drug: Avelumab

A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.


Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed

Primary Outcome Measures :
  1. Progression-free survival (PFS) according to the investigator [ Time Frame: up to 12 months ]
    Progression is defined as RECIST v1.1 criteria. Death is also considered as an event

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: up to 60 months ]
    Defined as death due to all causes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven colorectal adenocarcinoma with metastasis(es) non-resectable
  • MSI-H determined by immunohistochemistry (loss of expression of MLH1, MSH2, MSH6 and/or PMS2) or by molecular biology
  • At least one measurable target (primary tumor or metastasis) according to RECIST v1.1
  • Mutational status RAS and BRAF
  • Age ≥ 18
  • OMS ≤ 2
  • Life expectancy < 3 months
  • Patient failure (progression or unacceptable toxicity) of chemotherapy containing fluoropyrimidine (capecitabine or 5FU) +/- irinotecan +/- oxaliplatin with or without cetuximab, bevacizumab and panitumumab (patients in progression during or within 3 months after discontinuation of adjuvant chemotherapy are eligible)
  • PNN > 1500/mm3, platelets > 100 000/mm3, Hb > 9 g/dL
  • Total bilirubin < 25 µmol/L, ASAT < 5x LSN, ALAT < 5 x LSN, PT > 60%, , PAL<2.5 x LSN ( < 5 x LSN in case of hepatic metastasis)
  • Creatinine clearance > 50 ml/min according to MDRD formula (≥ 30 ml/min according to the Cockcroft-Gault formula)
  • Patient belonging to a social security scheme
  • Patient information and signature of the informed consent

Exclusion Criteria:

  • Patient immediately eligible for a curative therapy (surgical and/or percutaneous) after discussion in CPR
  • Patient treated with FOLFIRINOX or FOLFOXIRI in 1st line
  • Cerebral metastasis
  • Previous treatment with anti-PD1 or anti-PDL1
  • Autoimmune disease that might be aggravated during treatment with an immuno-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible)
  • Immunosuppressive long-term treatment (patients necessitating a corticotherapy are eligible if they are administered in doses < or = to the equivalent of 10 mg of prednisone daily, administration of steroids by a route resulting in minimal systemic exposure (local, intra-anal, intraocular or inhalation) are eligible).
  • Transplant patients (including stem cell transplants), HIV positive or other immune deficiency syndromes
  • Active infection by HBV or HCV
  • Known severe hypersensitivity to monoclonal antibodies or history of anaphylactic shock, or uncontrolled asthma
  • Any known specific contraindication or allergy to the treatments used in the study
  • Persistence of toxicities related to 1st line chemotherapy grade > 2 (NCI-CTC v4.0) (except alopecia and neuropathy sequelae of oxaliplatin)
  • Vaccination during the 4 weeks preceding the start of treatment
  • Known deficit in DPD
  • QT/QTc interval > 450 msec for men and > 470 msec for women
  • K+ < LIN, Mg2+ < LIN, Ca2+ < LIN
  • Following alterations in the 6 months prior to inclusion: myocardial infarction, angina, severe/unstable angina, coronary artery bypass surgery, congestive heart failure NYHA class II, III or IV, stroke or transient ischemic attack
  • Any progressive pathology not stabilised over the past 6 months: hepatic failure, renal failure, respiratory failure
  • Patient with interstitial pneumonitis or pulmonary fibrosis
  • History of chronic diarrhea or inflammatory disease of the colon or rectum, or unresolved occlusion or sub-occlusion in symptomatic treatment
  • History of malignant pathologies during the past 5 years except basocellular skin carcinoma or in situ cervical carcinoma, properly treated
  • Patient already included in another clinical trial during treatment with an experimental molecule for L2
  • Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women, women of childbearing age not having had a pregnancy test
  • Persons deprived of liberty or under supervision
  • Impossibility of undergoing medical monitoring during the trial for geographic, social or psychological reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03186326

Show Show 120 study locations
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Layout table for investigator information
Principal Investigator: Julien Taieb, Pr HOPITAL EUROPEEN G. POMPIDOU
Layout table for additonal information
Responsible Party: Federation Francophone de Cancerologie Digestive Identifier: NCT03186326    
Other Study ID Numbers: PRODIGE 54 - FFCD 1603
First Posted: June 14, 2017    Key Record Dates
Last Update Posted: August 19, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Federation Francophone de Cancerologie Digestive:
second line
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors